Eicosapentaenoic acid (EPA) from highly concentrated n −3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability

Abstract Objective To examine n −3 polyunsaturated fatty acid (PUFA) incorporation into atherosclerotic plaques and the association with plaque inflammation and stability. Methods and results Patients awaiting carotid endarterectomy ( n = 121) were randomised to consume control capsules or n −3 PUFA...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Atherosclerosis 2010-09, Vol.212 (1), p.252-259
Hauptverfasser: Cawood, Abbie L, Ding, Ren, Napper, Frances L, Young, Ruth H, Williams, Jennifer A, Ward, Matthew J.A, Gudmundsen, Ola, Vige, Runar, Payne, Simon P.K, Ye, Shu, Shearman, Ciff P, Gallagher, Patrick J, Grimble, Robert F, Calder, Philip C
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 259
container_issue 1
container_start_page 252
container_title Atherosclerosis
container_volume 212
creator Cawood, Abbie L
Ding, Ren
Napper, Frances L
Young, Ruth H
Williams, Jennifer A
Ward, Matthew J.A
Gudmundsen, Ola
Vige, Runar
Payne, Simon P.K
Ye, Shu
Shearman, Ciff P
Gallagher, Patrick J
Grimble, Robert F
Calder, Philip C
description Abstract Objective To examine n −3 polyunsaturated fatty acid (PUFA) incorporation into atherosclerotic plaques and the association with plaque inflammation and stability. Methods and results Patients awaiting carotid endarterectomy ( n = 121) were randomised to consume control capsules or n −3 PUFA ethyl ester capsules until surgery (median 21 days). The fatty acid compositions of plasma and carotid plaque phospholipids, plaque features, and expression of inflammatory genes were determined. The proportion of eicosapentaenoic acid (EPA) was higher ( P < 0.0001) in carotid plaque phospholipids in patients in the n −3 PUFA group. Plaques from patients in the n −3 PUFA group had fewer foam cells ( P = 0.0390). There were no other differences between plaques in the two groups with regard to histological characteristics or morphology. Plaque stability was not different between the two groups. However, the EPA content of plaque phospholipids was inversely associated with plaque instability ( P = 0.0209), plaque inflammation ( P = 0.0108), the number of T cells in the plaque ( P = 0.0097) and a summary score considering a range of plaque features ( P = 0.0425). Plaques from patients who received n −3 PUFAs had significantly lower levels of mRNA for matrix metalloproteinases (MMP)-7 ( P = 0.0055), -9 ( P = 0.0048) and -12 ( P = 0.0044) and for interleukin-6 ( P = 0.0395) and intercellular adhesion molecule 1 ( P = 0.0142). Conclusions Atherosclerotic plaques readily incorporate EPA. A higher plaque EPA content is associated with a reduced number of foam cells and T cells, less inflammation and increased stability.
doi_str_mv 10.1016/j.atherosclerosis.2010.05.022
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_753994694</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0021915010004004</els_id><sourcerecordid>753994694</sourcerecordid><originalsourceid>FETCH-LOGICAL-c473t-7e5b425a6bcd8f97f7e4a7819e7181841cb1916d986bfe71f099e38c93d261ba3</originalsourceid><addsrcrecordid>eNqNks9u1DAQxiMEotvCKyBfKuhhFzv_fQCpqpaCVAkk4GxNnAnrJbEX21uUN-DMI3LiMZjshgr1hGQlsvObbybf5yQ5F3wluChfblcQN-hd0P30NGGVcvrGixVP0wfJQtSVXIq8zh8mC85TsZSi4CfJaQhbznleifpxcpLyIk8LkS6S32ujXYAd2ghondEMtGnZi_WHywvWeTewjfmy6UemndUEeYjYMst-_fiZsQ5iHI8FGDdjzzBE9IEZWlY7v3NH3NjoGLS3QBIt-3f-SA13PXzbY2Bg20Mz9PMRoyEmLQjBaXNQ-m7ihrWoPUKg7cwZ2_UwDBCNswcZ6j4TIUJjehPHJ8mjDvqAT-f3WfL5zfrT1dvlzfvrd1eXN0udV1lcVlg0ZA2UjW7rTlZdhTlUtZBIzok6F7oRUpStrMumo7OOS4lZrWXWpqVoIDtLnh91d95NvxXVYILGvgeLbh9UVWRS5qXMiXx1JDW5ETx2aufNAH5Ugqspa7VV97JWU9aKF4qypvpnc6d9M2B7V_03XALOZwCChr7z5D9p3HFZmsms5sRdHzkkX24NehW0wSkr41FH1Trz3yO9vqeke2MNNf-KI4at23tL5iuhQqq4-jhd0Ol-iulq0sr-AKPm7VM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>753994694</pqid></control><display><type>article</type><title>Eicosapentaenoic acid (EPA) from highly concentrated n −3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Cawood, Abbie L ; Ding, Ren ; Napper, Frances L ; Young, Ruth H ; Williams, Jennifer A ; Ward, Matthew J.A ; Gudmundsen, Ola ; Vige, Runar ; Payne, Simon P.K ; Ye, Shu ; Shearman, Ciff P ; Gallagher, Patrick J ; Grimble, Robert F ; Calder, Philip C</creator><creatorcontrib>Cawood, Abbie L ; Ding, Ren ; Napper, Frances L ; Young, Ruth H ; Williams, Jennifer A ; Ward, Matthew J.A ; Gudmundsen, Ola ; Vige, Runar ; Payne, Simon P.K ; Ye, Shu ; Shearman, Ciff P ; Gallagher, Patrick J ; Grimble, Robert F ; Calder, Philip C</creatorcontrib><description>Abstract Objective To examine n −3 polyunsaturated fatty acid (PUFA) incorporation into atherosclerotic plaques and the association with plaque inflammation and stability. Methods and results Patients awaiting carotid endarterectomy ( n = 121) were randomised to consume control capsules or n −3 PUFA ethyl ester capsules until surgery (median 21 days). The fatty acid compositions of plasma and carotid plaque phospholipids, plaque features, and expression of inflammatory genes were determined. The proportion of eicosapentaenoic acid (EPA) was higher ( P &lt; 0.0001) in carotid plaque phospholipids in patients in the n −3 PUFA group. Plaques from patients in the n −3 PUFA group had fewer foam cells ( P = 0.0390). There were no other differences between plaques in the two groups with regard to histological characteristics or morphology. Plaque stability was not different between the two groups. However, the EPA content of plaque phospholipids was inversely associated with plaque instability ( P = 0.0209), plaque inflammation ( P = 0.0108), the number of T cells in the plaque ( P = 0.0097) and a summary score considering a range of plaque features ( P = 0.0425). Plaques from patients who received n −3 PUFAs had significantly lower levels of mRNA for matrix metalloproteinases (MMP)-7 ( P = 0.0055), -9 ( P = 0.0048) and -12 ( P = 0.0044) and for interleukin-6 ( P = 0.0395) and intercellular adhesion molecule 1 ( P = 0.0142). Conclusions Atherosclerotic plaques readily incorporate EPA. A higher plaque EPA content is associated with a reduced number of foam cells and T cells, less inflammation and increased stability.</description><identifier>ISSN: 0021-9150</identifier><identifier>EISSN: 1879-1484</identifier><identifier>DOI: 10.1016/j.atherosclerosis.2010.05.022</identifier><identifier>PMID: 20542512</identifier><language>eng</language><publisher>Amsterdam: Elsevier Ireland Ltd</publisher><subject>Administration, Oral ; Adult ; Aged ; Aged, 80 and over ; Atherosclerosis ; Atherosclerosis (general aspects, experimental research) ; Biological and medical sciences ; Blood and lymphatic vessels ; Capsules ; Cardiology. Vascular system ; Cardiovascular ; Carotid Artery Diseases - drug therapy ; Carotid Artery Diseases - immunology ; Carotid Artery Diseases - metabolism ; Carotid Artery Diseases - pathology ; Carotid Artery Diseases - surgery ; Chi-Square Distribution ; Coronary heart disease ; Cytokines - genetics ; Dietary Supplements ; Docosahexaenoic Acids - administration &amp; dosage ; Docosahexaenoic Acids - blood ; Double-Blind Method ; Drug Combinations ; Eicosapentaenoic Acid - administration &amp; dosage ; Eicosapentaenoic Acid - analogs &amp; derivatives ; Eicosapentaenoic Acid - blood ; Eicosapentaenoic Acid - metabolism ; Endarterectomy, Carotid ; England ; Fatty acid ; Female ; Foam Cells - drug effects ; Foam Cells - immunology ; Gene Expression Regulation ; Heart ; Humans ; Inflammation ; Inflammation - drug therapy ; Inflammation - immunology ; Inflammation - metabolism ; Inflammation - pathology ; Inflammation - surgery ; Inflammation Mediators - analysis ; Male ; Matrix Metalloproteinases - genetics ; Medical sciences ; Metalloproteinase ; Middle Aged ; Phospholipids - metabolism ; Plaque ; Preoperative Care ; RNA, Messenger - analysis ; Rupture, Spontaneous ; T-Lymphocytes - drug effects ; T-Lymphocytes - immunology ; Treatment Outcome</subject><ispartof>Atherosclerosis, 2010-09, Vol.212 (1), p.252-259</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2010 Elsevier Ireland Ltd</rights><rights>2015 INIST-CNRS</rights><rights>Copyright 2010 Elsevier Ireland Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c473t-7e5b425a6bcd8f97f7e4a7819e7181841cb1916d986bfe71f099e38c93d261ba3</citedby><cites>FETCH-LOGICAL-c473t-7e5b425a6bcd8f97f7e4a7819e7181841cb1916d986bfe71f099e38c93d261ba3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.atherosclerosis.2010.05.022$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,782,786,3554,27933,27934,46004</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=23239380$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20542512$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cawood, Abbie L</creatorcontrib><creatorcontrib>Ding, Ren</creatorcontrib><creatorcontrib>Napper, Frances L</creatorcontrib><creatorcontrib>Young, Ruth H</creatorcontrib><creatorcontrib>Williams, Jennifer A</creatorcontrib><creatorcontrib>Ward, Matthew J.A</creatorcontrib><creatorcontrib>Gudmundsen, Ola</creatorcontrib><creatorcontrib>Vige, Runar</creatorcontrib><creatorcontrib>Payne, Simon P.K</creatorcontrib><creatorcontrib>Ye, Shu</creatorcontrib><creatorcontrib>Shearman, Ciff P</creatorcontrib><creatorcontrib>Gallagher, Patrick J</creatorcontrib><creatorcontrib>Grimble, Robert F</creatorcontrib><creatorcontrib>Calder, Philip C</creatorcontrib><title>Eicosapentaenoic acid (EPA) from highly concentrated n −3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability</title><title>Atherosclerosis</title><addtitle>Atherosclerosis</addtitle><description>Abstract Objective To examine n −3 polyunsaturated fatty acid (PUFA) incorporation into atherosclerotic plaques and the association with plaque inflammation and stability. Methods and results Patients awaiting carotid endarterectomy ( n = 121) were randomised to consume control capsules or n −3 PUFA ethyl ester capsules until surgery (median 21 days). The fatty acid compositions of plasma and carotid plaque phospholipids, plaque features, and expression of inflammatory genes were determined. The proportion of eicosapentaenoic acid (EPA) was higher ( P &lt; 0.0001) in carotid plaque phospholipids in patients in the n −3 PUFA group. Plaques from patients in the n −3 PUFA group had fewer foam cells ( P = 0.0390). There were no other differences between plaques in the two groups with regard to histological characteristics or morphology. Plaque stability was not different between the two groups. However, the EPA content of plaque phospholipids was inversely associated with plaque instability ( P = 0.0209), plaque inflammation ( P = 0.0108), the number of T cells in the plaque ( P = 0.0097) and a summary score considering a range of plaque features ( P = 0.0425). Plaques from patients who received n −3 PUFAs had significantly lower levels of mRNA for matrix metalloproteinases (MMP)-7 ( P = 0.0055), -9 ( P = 0.0048) and -12 ( P = 0.0044) and for interleukin-6 ( P = 0.0395) and intercellular adhesion molecule 1 ( P = 0.0142). Conclusions Atherosclerotic plaques readily incorporate EPA. A higher plaque EPA content is associated with a reduced number of foam cells and T cells, less inflammation and increased stability.</description><subject>Administration, Oral</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Atherosclerosis</subject><subject>Atherosclerosis (general aspects, experimental research)</subject><subject>Biological and medical sciences</subject><subject>Blood and lymphatic vessels</subject><subject>Capsules</subject><subject>Cardiology. Vascular system</subject><subject>Cardiovascular</subject><subject>Carotid Artery Diseases - drug therapy</subject><subject>Carotid Artery Diseases - immunology</subject><subject>Carotid Artery Diseases - metabolism</subject><subject>Carotid Artery Diseases - pathology</subject><subject>Carotid Artery Diseases - surgery</subject><subject>Chi-Square Distribution</subject><subject>Coronary heart disease</subject><subject>Cytokines - genetics</subject><subject>Dietary Supplements</subject><subject>Docosahexaenoic Acids - administration &amp; dosage</subject><subject>Docosahexaenoic Acids - blood</subject><subject>Double-Blind Method</subject><subject>Drug Combinations</subject><subject>Eicosapentaenoic Acid - administration &amp; dosage</subject><subject>Eicosapentaenoic Acid - analogs &amp; derivatives</subject><subject>Eicosapentaenoic Acid - blood</subject><subject>Eicosapentaenoic Acid - metabolism</subject><subject>Endarterectomy, Carotid</subject><subject>England</subject><subject>Fatty acid</subject><subject>Female</subject><subject>Foam Cells - drug effects</subject><subject>Foam Cells - immunology</subject><subject>Gene Expression Regulation</subject><subject>Heart</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Inflammation - drug therapy</subject><subject>Inflammation - immunology</subject><subject>Inflammation - metabolism</subject><subject>Inflammation - pathology</subject><subject>Inflammation - surgery</subject><subject>Inflammation Mediators - analysis</subject><subject>Male</subject><subject>Matrix Metalloproteinases - genetics</subject><subject>Medical sciences</subject><subject>Metalloproteinase</subject><subject>Middle Aged</subject><subject>Phospholipids - metabolism</subject><subject>Plaque</subject><subject>Preoperative Care</subject><subject>RNA, Messenger - analysis</subject><subject>Rupture, Spontaneous</subject><subject>T-Lymphocytes - drug effects</subject><subject>T-Lymphocytes - immunology</subject><subject>Treatment Outcome</subject><issn>0021-9150</issn><issn>1879-1484</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNks9u1DAQxiMEotvCKyBfKuhhFzv_fQCpqpaCVAkk4GxNnAnrJbEX21uUN-DMI3LiMZjshgr1hGQlsvObbybf5yQ5F3wluChfblcQN-hd0P30NGGVcvrGixVP0wfJQtSVXIq8zh8mC85TsZSi4CfJaQhbznleifpxcpLyIk8LkS6S32ujXYAd2ghondEMtGnZi_WHywvWeTewjfmy6UemndUEeYjYMst-_fiZsQ5iHI8FGDdjzzBE9IEZWlY7v3NH3NjoGLS3QBIt-3f-SA13PXzbY2Bg20Mz9PMRoyEmLQjBaXNQ-m7ihrWoPUKg7cwZ2_UwDBCNswcZ6j4TIUJjehPHJ8mjDvqAT-f3WfL5zfrT1dvlzfvrd1eXN0udV1lcVlg0ZA2UjW7rTlZdhTlUtZBIzok6F7oRUpStrMumo7OOS4lZrWXWpqVoIDtLnh91d95NvxXVYILGvgeLbh9UVWRS5qXMiXx1JDW5ETx2aufNAH5Ugqspa7VV97JWU9aKF4qypvpnc6d9M2B7V_03XALOZwCChr7z5D9p3HFZmsms5sRdHzkkX24NehW0wSkr41FH1Trz3yO9vqeke2MNNf-KI4at23tL5iuhQqq4-jhd0Ol-iulq0sr-AKPm7VM</recordid><startdate>20100901</startdate><enddate>20100901</enddate><creator>Cawood, Abbie L</creator><creator>Ding, Ren</creator><creator>Napper, Frances L</creator><creator>Young, Ruth H</creator><creator>Williams, Jennifer A</creator><creator>Ward, Matthew J.A</creator><creator>Gudmundsen, Ola</creator><creator>Vige, Runar</creator><creator>Payne, Simon P.K</creator><creator>Ye, Shu</creator><creator>Shearman, Ciff P</creator><creator>Gallagher, Patrick J</creator><creator>Grimble, Robert F</creator><creator>Calder, Philip C</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20100901</creationdate><title>Eicosapentaenoic acid (EPA) from highly concentrated n −3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability</title><author>Cawood, Abbie L ; Ding, Ren ; Napper, Frances L ; Young, Ruth H ; Williams, Jennifer A ; Ward, Matthew J.A ; Gudmundsen, Ola ; Vige, Runar ; Payne, Simon P.K ; Ye, Shu ; Shearman, Ciff P ; Gallagher, Patrick J ; Grimble, Robert F ; Calder, Philip C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c473t-7e5b425a6bcd8f97f7e4a7819e7181841cb1916d986bfe71f099e38c93d261ba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Administration, Oral</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Atherosclerosis</topic><topic>Atherosclerosis (general aspects, experimental research)</topic><topic>Biological and medical sciences</topic><topic>Blood and lymphatic vessels</topic><topic>Capsules</topic><topic>Cardiology. Vascular system</topic><topic>Cardiovascular</topic><topic>Carotid Artery Diseases - drug therapy</topic><topic>Carotid Artery Diseases - immunology</topic><topic>Carotid Artery Diseases - metabolism</topic><topic>Carotid Artery Diseases - pathology</topic><topic>Carotid Artery Diseases - surgery</topic><topic>Chi-Square Distribution</topic><topic>Coronary heart disease</topic><topic>Cytokines - genetics</topic><topic>Dietary Supplements</topic><topic>Docosahexaenoic Acids - administration &amp; dosage</topic><topic>Docosahexaenoic Acids - blood</topic><topic>Double-Blind Method</topic><topic>Drug Combinations</topic><topic>Eicosapentaenoic Acid - administration &amp; dosage</topic><topic>Eicosapentaenoic Acid - analogs &amp; derivatives</topic><topic>Eicosapentaenoic Acid - blood</topic><topic>Eicosapentaenoic Acid - metabolism</topic><topic>Endarterectomy, Carotid</topic><topic>England</topic><topic>Fatty acid</topic><topic>Female</topic><topic>Foam Cells - drug effects</topic><topic>Foam Cells - immunology</topic><topic>Gene Expression Regulation</topic><topic>Heart</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Inflammation - drug therapy</topic><topic>Inflammation - immunology</topic><topic>Inflammation - metabolism</topic><topic>Inflammation - pathology</topic><topic>Inflammation - surgery</topic><topic>Inflammation Mediators - analysis</topic><topic>Male</topic><topic>Matrix Metalloproteinases - genetics</topic><topic>Medical sciences</topic><topic>Metalloproteinase</topic><topic>Middle Aged</topic><topic>Phospholipids - metabolism</topic><topic>Plaque</topic><topic>Preoperative Care</topic><topic>RNA, Messenger - analysis</topic><topic>Rupture, Spontaneous</topic><topic>T-Lymphocytes - drug effects</topic><topic>T-Lymphocytes - immunology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cawood, Abbie L</creatorcontrib><creatorcontrib>Ding, Ren</creatorcontrib><creatorcontrib>Napper, Frances L</creatorcontrib><creatorcontrib>Young, Ruth H</creatorcontrib><creatorcontrib>Williams, Jennifer A</creatorcontrib><creatorcontrib>Ward, Matthew J.A</creatorcontrib><creatorcontrib>Gudmundsen, Ola</creatorcontrib><creatorcontrib>Vige, Runar</creatorcontrib><creatorcontrib>Payne, Simon P.K</creatorcontrib><creatorcontrib>Ye, Shu</creatorcontrib><creatorcontrib>Shearman, Ciff P</creatorcontrib><creatorcontrib>Gallagher, Patrick J</creatorcontrib><creatorcontrib>Grimble, Robert F</creatorcontrib><creatorcontrib>Calder, Philip C</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Atherosclerosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cawood, Abbie L</au><au>Ding, Ren</au><au>Napper, Frances L</au><au>Young, Ruth H</au><au>Williams, Jennifer A</au><au>Ward, Matthew J.A</au><au>Gudmundsen, Ola</au><au>Vige, Runar</au><au>Payne, Simon P.K</au><au>Ye, Shu</au><au>Shearman, Ciff P</au><au>Gallagher, Patrick J</au><au>Grimble, Robert F</au><au>Calder, Philip C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Eicosapentaenoic acid (EPA) from highly concentrated n −3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability</atitle><jtitle>Atherosclerosis</jtitle><addtitle>Atherosclerosis</addtitle><date>2010-09-01</date><risdate>2010</risdate><volume>212</volume><issue>1</issue><spage>252</spage><epage>259</epage><pages>252-259</pages><issn>0021-9150</issn><eissn>1879-1484</eissn><abstract>Abstract Objective To examine n −3 polyunsaturated fatty acid (PUFA) incorporation into atherosclerotic plaques and the association with plaque inflammation and stability. Methods and results Patients awaiting carotid endarterectomy ( n = 121) were randomised to consume control capsules or n −3 PUFA ethyl ester capsules until surgery (median 21 days). The fatty acid compositions of plasma and carotid plaque phospholipids, plaque features, and expression of inflammatory genes were determined. The proportion of eicosapentaenoic acid (EPA) was higher ( P &lt; 0.0001) in carotid plaque phospholipids in patients in the n −3 PUFA group. Plaques from patients in the n −3 PUFA group had fewer foam cells ( P = 0.0390). There were no other differences between plaques in the two groups with regard to histological characteristics or morphology. Plaque stability was not different between the two groups. However, the EPA content of plaque phospholipids was inversely associated with plaque instability ( P = 0.0209), plaque inflammation ( P = 0.0108), the number of T cells in the plaque ( P = 0.0097) and a summary score considering a range of plaque features ( P = 0.0425). Plaques from patients who received n −3 PUFAs had significantly lower levels of mRNA for matrix metalloproteinases (MMP)-7 ( P = 0.0055), -9 ( P = 0.0048) and -12 ( P = 0.0044) and for interleukin-6 ( P = 0.0395) and intercellular adhesion molecule 1 ( P = 0.0142). Conclusions Atherosclerotic plaques readily incorporate EPA. A higher plaque EPA content is associated with a reduced number of foam cells and T cells, less inflammation and increased stability.</abstract><cop>Amsterdam</cop><pub>Elsevier Ireland Ltd</pub><pmid>20542512</pmid><doi>10.1016/j.atherosclerosis.2010.05.022</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0021-9150
ispartof Atherosclerosis, 2010-09, Vol.212 (1), p.252-259
issn 0021-9150
1879-1484
language eng
recordid cdi_proquest_miscellaneous_753994694
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Administration, Oral
Adult
Aged
Aged, 80 and over
Atherosclerosis
Atherosclerosis (general aspects, experimental research)
Biological and medical sciences
Blood and lymphatic vessels
Capsules
Cardiology. Vascular system
Cardiovascular
Carotid Artery Diseases - drug therapy
Carotid Artery Diseases - immunology
Carotid Artery Diseases - metabolism
Carotid Artery Diseases - pathology
Carotid Artery Diseases - surgery
Chi-Square Distribution
Coronary heart disease
Cytokines - genetics
Dietary Supplements
Docosahexaenoic Acids - administration & dosage
Docosahexaenoic Acids - blood
Double-Blind Method
Drug Combinations
Eicosapentaenoic Acid - administration & dosage
Eicosapentaenoic Acid - analogs & derivatives
Eicosapentaenoic Acid - blood
Eicosapentaenoic Acid - metabolism
Endarterectomy, Carotid
England
Fatty acid
Female
Foam Cells - drug effects
Foam Cells - immunology
Gene Expression Regulation
Heart
Humans
Inflammation
Inflammation - drug therapy
Inflammation - immunology
Inflammation - metabolism
Inflammation - pathology
Inflammation - surgery
Inflammation Mediators - analysis
Male
Matrix Metalloproteinases - genetics
Medical sciences
Metalloproteinase
Middle Aged
Phospholipids - metabolism
Plaque
Preoperative Care
RNA, Messenger - analysis
Rupture, Spontaneous
T-Lymphocytes - drug effects
T-Lymphocytes - immunology
Treatment Outcome
title Eicosapentaenoic acid (EPA) from highly concentrated n −3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-02T17%3A47%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Eicosapentaenoic%20acid%20(EPA)%20from%20highly%20concentrated%20n%20%E2%88%923%20fatty%20acid%20ethyl%20esters%20is%20incorporated%20into%20advanced%20atherosclerotic%20plaques%20and%20higher%20plaque%20EPA%20is%20associated%20with%20decreased%20plaque%20inflammation%20and%20increased%20stability&rft.jtitle=Atherosclerosis&rft.au=Cawood,%20Abbie%20L&rft.date=2010-09-01&rft.volume=212&rft.issue=1&rft.spage=252&rft.epage=259&rft.pages=252-259&rft.issn=0021-9150&rft.eissn=1879-1484&rft_id=info:doi/10.1016/j.atherosclerosis.2010.05.022&rft_dat=%3Cproquest_cross%3E753994694%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=753994694&rft_id=info:pmid/20542512&rft_els_id=S0021915010004004&rfr_iscdi=true